This week, we will discuss the applicable NIOSH Tables of interest and note that NIOSH may be easier to be compliant with than USP standards, especially when looking at Table 5!
Step #1: Prepare your own list of Hazardous Drugs (HDs) using Tables 1-3 as your guide.
- Check with your state board of pharmacy to see which tables they will be enforcing. Some may only be interested in Table 1, the Antineoplastic Drugs, which are the most serious (most have MSHGs); Tables 2 and 3 may be handled differently.
- Regarding Table 3, reassignment of personnel may be an alternative method of handling these drugs with potential reproductive issues and use only personnel (male or female) not planning on any pregnancies or not of child-bearing age, etc.
Step #2: Utilize Table 5 for personal protective equipment and engineering controls for working with hazardous drugs in healthcare settings. This Table lists the following column headers:
Formulation |
Activity |
Double Chemo-therapy Gloves |
Protective Gown |
Eye/face Protection |
Respiratory Protection |
Ventilated Engineering Control |
|
|
|
|
|
|
|
By checking the requirements for the specific formulation (e.g., tablet, capsule, liquid, injection, topical), the requirements are listed and are much briefer than USP Chapter <800> and are enforceable. There is much more “flexibility� in meeting these standards, which are provided in 3 simple pages, as compared to the strict 19-page, single-spaced document in the USP.
Table 5 has some important footnotes, as follows:
*This NIOSH guidance applies to drugs in Tables 1-3.
†For nonsterile preparations, a ventilated engineering control such as a fume hood or Class I BSC or a HEPA-filtered enclosure (such as a powder hood) is sufficient if the control device exhaust is HEPA-filtered or appropriately exhausted to the outside of the building. It is recommended that these activities be carried out in a control device, but it is recognized that under some circumstances, it is not possible. If the activity is performed in a ventilated engineering control that is used for sterile intravenous preparations, a thorough cleaning is required following the activity.
Bottom Line: NIOSH seems more reasonable than USP Chapter <800> to comply with.
Next, we will complete our briefing of the NIOSH Document by looking at enforcement priorities, etc.
Reference:
https://www.cdc.gov/niosh/docs/2016-161/pdfs/2016-161.pdf?id=10.26616/NIOSHPUB2016161
Loyd V. Allen, Jr., PhD, RPh
Editor-in-Chief
International Journal of Pharmaceutical Compounding
Remington: The Science and Practice of Pharmacy Twenty-second edition
|